

Jens Cosedis Nielsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2114310/publications.pdf>

Version: 2024-02-01

199
papers

13,257
citations

71102

41
h-index

24258

110
g-index

200
all docs

200
docs citations

200
times ranked

10420
citing authors

#	ARTICLE	IF	CITATIONS
1	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. Europace, 2023, 25, .	1.7	2
2	Cardiac surgery in patients with cardiac implantable electronic devices and risk of device infections: a nationwide nested caseâ€“control study. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 897-904.	1.3	2
3	Non-infective left ventricular lead complications requiring re-intervention following cardiac resynchronization therapy: prevalence, causes and outcomes. Journal of Interventional Cardiac Electrophysiology, 2022, 63, 69-75.	1.3	5
4	Outcomes of conduction system pacing compared to right ventricular pacing as a primary strategy for treating bradyarrhythmia: systematic review and meta-analysis. Clinical Research in Cardiology, 2022, 111, 1198-1209.	3.3	18
5	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	1.7	370
6	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	1.7	20
7	Rate of device-related infections using an antibacterial envelope in patients undergoing cardiac resynchronization therapy reoperations. Europace, 2022, 24, 421-429.	1.7	6
8	Rate of permanent cardiac implantable electronic device infections after active fixation temporary transvenous pacing: A nationwide Danish cohort study. Heart Rhythm O2, 2022, 3, 50-56.	1.7	2
9	Long-term outcomes in a randomized controlled trial of multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy. Europace, 2022, 24, 828-834.	1.7	16
10	Recurrent atrial arrhythmia in a randomised controlled trial comparing contact forceâ€“guided and contact forceâ€“blinded ablation for typical atrial flutter. Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	1.3	2
11	2021 ESC guidelines on cardiac pacing and cardiac resynchronization: what is the correct level of evidence for the superiority of cephalic vein cutdown? C, B or maybe A?â€“Authorâ€™s reply. Europace, 2022, , .	1.7	0
12	Effect of implantable cardioverterâ€“defibrillators in patients with nonâ€“ischaemic systolic heart failure and concurrent coronary atherosclerosis. ESC Heart Failure, 2022, 9, 1287-1293.	3.1	1
13	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq1 1 0.784314 rgBT /Overl	1.6	28
14	Microbiological diagnosis in cardiac implantable electronic device infections detected by sonication and next-generation sequencing. Heart Rhythm, 2022, 19, 901-908.	0.7	8
15	MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation, 2022, 145, 906-915.	1.6	12
16	Familial risk of atrioventricular block in first-degree relatives. Heart, 2022, 108, 1194-1199.	2.9	3
17	NT-proBNP and ICD in Nonischemic Systolic Heartâ€“Failure. JACC: Heart Failure, 2022, 10, 161-171.	4.1	4
18	Cardiac computed tomography-verified right ventricular lead position and outcomes in cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy. <i>Circulation</i> , 2022, 145, 754-764.	1.6	5
20	Two case reports of transcatheter valve-in-valve implantation of Sapien 3 and MyVal in degenerated biological tricuspid prosthesis valves. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac131.	0.6	3
21	OUP accepted manuscript. <i>Europace</i> , 2022, , .	1.7	1
22	Diagnostic Yield of Genetic Testing in Young Patients With Atrioventricular Block of Unknown Cause. <i>Journal of the American Heart Association</i> , 2022, 11, e025643.	3.7	2
23	Troubleshooting the difficult left ventricular lead placement in cardiac resynchronization therapy: current status and future perspectives. <i>Expert Review of Medical Devices</i> , 2022, 19, 341-352.	2.8	0
24	Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failure—Results from the DANISH trial. <i>American Heart Journal</i> , 2021, 232, 61-70.	2.7	2
25	Avoiding implant complications in cardiac implantable electronic devices: what works?. <i>Europace</i> , 2021, 23, 163-173.	1.7	14
26	Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial. <i>Europace</i> , 2021, 23, 587-595.	1.7	10
27	Use of a snare to aid implanting leadless pacemaker in a patient with severely dilated atria. <i>Europace</i> , 2021, 23, 246-246.	1.7	4
28	Investigating sudden cardiac death – A new paradigm. <i>Heart Rhythm O2</i> , 2021, 2, 3-4.	1.7	0
29	Long-term outcomes in young patients with atrioventricular block of unknown aetiology. <i>European Heart Journal</i> , 2021, 42, 2060-2068.	2.2	24
30	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	1.7	18
31	Driving following defibrillator implantation: a nationwide register-linked survey study. <i>European Heart Journal</i> , 2021, 42, 3529-3537.	2.2	5
32	Temporal Incidence of Appropriate and Inappropriate Therapy and Mortality in Secondary Prevention ICD Patients by Cardiac Diagnosis. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 781-792.	3.2	6
33	Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: A nation-wide Danish cohort study. <i>International Journal of Cardiology</i> , 2021, 333, 110-116.	1.7	7
34	EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2021, 23, 983-1008.	1.7	92
35	The “10 commandments” for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 4295-4295.	2.2	79
36	New onset anxiety and depression in patients with an implantable cardioverter defibrillator during 24 months of follow-up (data from the national DEFIB-WOMEN study). <i>General Hospital Psychiatry</i> , 2021, 72, 59-65.	2.4	18

#	ARTICLE	IF	CITATIONS
37	Risk of Cardiac Implantable Electronic Device Malfunctioning During Pencil Beam Proton Scanning in an In Vitro Setting. International Journal of Radiation Oncology Biology Physics, 2021, 111, 186-195.	0.8	6
38	Reversible Complete Heart Block in a Pregnant Woman Related to Sertraline-Treatment. CJC Open, 2021, 4, 240-242.	1.5	1
39	Contemporary Patients With Congenital Heart Disease. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009695.	4.8	3
40	EHRA/HRS/APHRS/LAHRs expert consensus on risk assessment in cardiac arrhythmias: Authors' reply. Europace, 2021, 23, 649-649.	1.7	1
41	CHA ₂ DS ₂ -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. European Journal of Clinical Investigation, 2021, , e13717.	3.4	0
42	Appropriate timing of electrophysiological study in myotonic dystrophy type 1: <i>unsolved question</i>"Authorsâ€™ reply. Europace, 2021, , .	1.7	1
43	Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: A nation-wide Danish cohort study. International Journal of Cardiology, 2020, 298, 44-51.	1.7	14
44	Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 2020, 109, 638-645.	3.3	12
45	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. Europace, 2020, 22, 515-549.	1.7	216
46	The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. European Heart Journal, 2020, 41, 2003-2011.	2.2	22
47	Burden of Premature Atrial Complexes and Risk of Recurrent Stroke and Death in Patients with Mild to Moderate Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104490.	1.6	3
48	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. European Journal of Cardio-thoracic Surgery, 2020, 57, e1-e31.	1.4	111
49	Left Atrial Function Determined by Cardiac Computed Tomography Predicts Device-Detected Atrial High-Rate Episodes in Patients Treated With Cardiac Resynchronization Therapy. Journal of Computer Assisted Tomography, 2020, 44, 784-789.	0.9	2
50	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. Heart, 2020, 106, 1919-1926.	2.9	17
51	Risk Assessment in Cardiac Arrhythmias. European Heart Journal, 2020, 41, 4455-4457.	2.2	0
52	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace, 2020, 22, 1337-1344.	1.7	21
53	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	7.1	101
54	Anxiety and depression symptoms in Danish patients with an implantable cardioverter-defibrillator: prevalence and association with indication and sex up to 2 years of follow-up (data from the national) Tj ETQq0 0 OrgBT /Overlock 10 Tf		

#	ARTICLE	IF	CITATIONS
55	Reproducibility and repeatability of identifying the latest electrical activation during mapping of coronary sinus branches in CRT recipients. Journal of Cardiovascular Electrophysiology, 2020, 31, 2940-2947.	1.7	1
56	Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. Europace, 2020, 22, 1742-1758.	1.7	32
57	Self-reported health status and the associated risk of mortality in heart failure: The DANISH trial. Journal of Psychosomatic Research, 2020, 137, 110220.	2.6	6
58	Long-term follow-up of abandoned transvenous defibrillator leads: a nationwide cohort study. Europace, 2020, 22, 1097-1102.	1.7	6
59	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020, 22, 1147-1148.	1.7	62
60	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Journal of Arrhythmia, 2020, 36, 553-607.	1.2	40
61	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm, 2020, 17, e269-e316.	0.7	15
62	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace, 2020, 22, 1026-1035.	1.7	26
63	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardiol. European Heart Journal, 2020, 41, 2012-2032.	2.2	120
64	Quality of life and the associated risk of all-cause mortality in nonischemic heart failure. International Journal of Cardiology, 2020, 305, 92-98.	1.7	7
65	Is a ring of gold what we waited for to treat atrial fibrillation?. Europace, 2020, 22, 841-842.	1.7	0
66	The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction. European Heart Journal, 2020, 41, 2035-2035.	2.2	1
67	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
68	A randomized trial of contact force in atrial flutter ablation. Europace, 2020, 22, 947-955.	1.7	11
69	Electroanatomical mapping— and CT scan image integration—guided pacing lead implantation: A case series and review of the recent literature. Heart Rhythm O2, 2020, 1, 341-350.	1.7	3
70	Remote monitoring and clinical outcomes: details on information flow and workflow in the IN-TIME study. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 136-144.	4.0	13
71	Multisize Electrodes for Substrate Identification in Ischemic Cardiomyopathy. JACC: Clinical Electrophysiology, 2019, 5, 1130-1140.	3.2	23
72	Aetiologies and temporal trends of atrioventricular block in young patients: a 20-year nationwide study. Europace, 2019, 21, 1710-1716.	1.7	25

#	ARTICLE	IF	CITATIONS
73	Association between Type D personality and outcomes in patients with non-ischemic heart failure. Quality of Life Research, 2019, 28, 2901-2908.	3.1	10
74	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. JACC: Heart Failure, 2019, 7, 717-724.	4.1	29
75	Electrically vs. imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Europace, 2019, 21, 1369-1377.	1.7	32
76	Radiofrequency ablation lesions in low-, intermediate-, and normal-voltage myocardium: an in vivo study in a porcine heart model. Europace, 2019, 21, 1919-1927.	1.7	28
77	Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. Circulation: Heart Failure, 2019, 12, e006022.	3.9	2
78	Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study. Europace, 2019, 21, 465-474.	1.7	7
79	Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. Europace, 2019, 21, 1270-1279.	1.7	49
80	Incidence of device-related infection in 97Â750 patients: clinical data from the complete Danish device-cohort (1982â2018). European Heart Journal, 2019, 40, 1862-1869.	2.2	136
81	Outcome after catheter ablation for left atrial flutter. Scandinavian Cardiovascular Journal, 2019, 53, 133-140.	1.2	8
82	The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace, 2019, 21, 1203-1210.	1.7	9
83	Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort. Europace, 2019, 21, 1211-1219.	1.7	9
84	External continuous ECG versus loop recording for atrial fibrillation detection in patients who had a stroke. Heart, 2019, 105, 848-854.	2.9	10
85	Predicting stroke in patients without atrial fibrillation. European Journal of Clinical Investigation, 2019, 49, e13103.	3.4	5
86	Appropriate use of genetics in a young patient with atrioventricular block and family history of sudden cardiac death. HeartRhythm Case Reports, 2019, 5, 169-172.	0.4	5
87	Implant-based multi-parameter telemonitoring of patients with heart failure and a defibrillator with vs. without cardiac resynchronization therapy option: a subanalysis of the IN-TIME trial. Clinical Research in Cardiology, 2019, 108, 1117-1127.	3.3	23
88	The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. Europace, 2019, 21, 900-908.	1.7	10
89	Significant regional variation in use of implantable cardioverter-defibrillators in Denmark. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 352-360.	4.0	3
90	Hidden burden of arrhythmias in patients with small atrial septal defects: a nationwide study. Open Heart, 2019, 6, e001056.	2.3	6

#	ARTICLE	IF	CITATIONS
91	Survey on the research activities within the EHRA Young EP community. <i>Europace</i> , 2019, 21, 670-672.	1.7	1
92	Current status of interventional cardiac electrophysiology training in ESC member countries: an EHRA Young EP Report. <i>Europace</i> , 2019, 21, 522-524.	1.7	4
93	Reproducibility of measuring QRS duration and implications for optimization of interventricular pacing delay in cardiac resynchronization therapy. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12621.	1.1	7
94	Left ventricular regional remodeling and lead position during cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2018, 15, 1542-1549.	0.7	4
95	Association between right ventricular lead position and clinical outcomes in patients with cardiac resynchronization therapy. <i>Europace</i> , 2018, 20, 629-635.	1.7	7
96	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Europace</i> , 2018, 20, e1-e160.	1.7	767
97	Longer inter-lead electrical delay is associated with response to cardiac resynchronization therapy in patients with presumed optimal left ventricular lead position. <i>Europace</i> , 2018, 20, 1630-1637.	1.7	14
98	Targeted next generation sequencing in a young population with suspected inherited malignant cardiac arrhythmias. <i>European Journal of Human Genetics</i> , 2018, 26, 303-313.	2.8	7
99	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Europace</i> , 2018, 20, 157-208.	1.7	375
100	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	1.7	95
101	Implantable cardioverter-defibrillator therapy and device-related complications in young patients with inherited cardiomyopathies or channelopathies: a 17-year cohort study. <i>Europace</i> , 2018, 20, 1849-1855.	1.7	3
102	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRs. <i>Europace</i> , 2018, 20, 1217-1217.	1.7	243
103	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018, 39, 2942-2955.	2.2	181
104	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRs). <i>Europace</i> , 2018, 20, 895-896.	1.7	24
105	Higher burden of supraventricular ectopic complexes early after catheter ablation for atrial fibrillation is associated with increased risk of recurrent atrial fibrillation. <i>Europace</i> , 2018, 20, 50-57.	1.7	15
106	The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers. <i>Europace</i> , 2018, 20, 301-307.	1.7	6
107	QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy. <i>CNS Spectrums</i> , 2018, 23, 278-283.	1.2	18
108	Association between implantable cardioverter-defibrillator therapy and different lead positions in patients with cardiac resynchronization therapy. <i>Europace</i> , 2018, 20, e133-e139.	1.7	4

#	ARTICLE	IF	CITATIONS
109	The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation. <i>International Journal of Cardiology</i> , 2018, 250, 122-127.	1.7	6
110	Recurrence after pulmonary vein isolation is associated with low contact force. <i>Scandinavian Cardiovascular Journal</i> , 2018, 52, 28-33.	1.2	3
111	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2162-2170.	3.4	32
112	Electrically guided versus imaging-guided implant of the left ventricular lead in cardiac resynchronization therapy: a study protocol for a double-blinded randomized controlled clinical trial (ElectroCRT). <i>Trials</i> , 2018, 19, 600.	1.6	7
113	Time until diagnosis of clinical events with different remote monitoring systems in implantable cardioverter-defibrillator patients. <i>Heart Rhythm</i> , 2018, 15, 1648-1654.	0.7	9
114	Effectiveness of a comprehensive interactive eHealth intervention on patient-reported and clinical outcomes in patients with an implantable cardioverter defibrillator [ACQUIRE-ICD trial]: study protocol of a national Danish randomised controlled trial. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 136.	1.7	8
115	The time is not ripe for the wearable cardioverter-defibrillator. <i>Europace</i> , 2018, 20, f146-f147.	1.7	0
116	Validation of defibrillator lead performance registry data: insight from the Danish Pacemaker and ICD Register. <i>Europace</i> , 2017, 19, euw226.	1.7	1
117	Single lead atrial vs. dual chamber pacing in sick sinus syndrome: extended register-based follow-up in the DANPACE trial. <i>Europace</i> , 2017, 19, 1981-1987.	1.7	21
118	Atrial fibrillation detected by external loop recording for seven days or two-day simultaneous Holter recording: A comparison in patients with ischemic stroke or transient ischemic attack. <i>Journal of Electrocardiology</i> , 2017, 50, 287-293.	0.9	11
119	Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. <i>Heart</i> , 2017, 103, 368-376.	2.9	74
120	Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations. <i>Heart</i> , 2017, 103, 901-909.	2.9	20
121	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Heart Rhythm</i> , 2017, 14, e275-e444.	0.7	1,671
122	Left atrial size and function as assessed by computed tomography in cardiac resynchronization therapy: Association to echocardiographic and clinical outcome. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 917-925.	1.5	5
123	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	2.7	258
124	The impact of comorbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers. <i>European Journal of Heart Failure</i> , 2017, 19, 377-386.	7.1	42
125	Antiarrhythmic medication is superior to catheter ablation in suppressing supraventricular ectopic complexes in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 244, 186-191.	1.7	6
126	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 447-455.	1.5	3

#	ARTICLE	IF	CITATIONS
127	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. <i>Europace</i> , 2017, 19, 132-138.	1.7	32
128	Is the knowledge of contact force beneficial in pulmonary vein antrum isolation?. <i>Scandinavian Cardiovascular Journal</i> , 2017, 51, 129-137.	1.2	9
129	ICD Implantation in Patients with Nonischemic Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 89-92.	27.0	7
130	HRS Clinical Document Development Methodology Manual and Policies: Executive summary. <i>Heart Rhythm</i> , 2017, 14, e495-e500.	0.7	16
131	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Journal of Arrhythmia</i> , 2017, 33, 369-409.	1.2	348
132	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 1-55.	1.3	83
133	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Heart Rhythm</i> , 2017, 14, e445-e494.	0.7	135
134	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. <i>Circulation</i> , 2017, 136, 1772-1780.	1.6	134
135	Safety and effectiveness of a 6â€¢French MRI conditional pacemaker lead: The INGEVITYTM clinical investigation study results. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 1121-1128.	1.2	3
136	Guided left ventricular lead placement for cardiac resynchronization therapy â€“ an opportunity for image integration: reply. <i>European Journal of Heart Failure</i> , 2017, 19, 1344-1344.	7.1	0
137	Coronary artery disease and risk of adverse cardiac events and stroke. <i>European Journal of Clinical Investigation</i> , 2017, 47, 819-828.	3.4	23
138	A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Procedures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association. <i>Europace</i> , 2017, 19, ii1-ii90.	1.7	216
139	Management of Cardiac Electronic Device Infections: Challenges and Outcomes. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 183.	2.4	27
140	Multimodality imagingâ€¢Guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1365-1374.	7.1	103
141	His Bundle Pacing: Techniques and Outcomes. <i>Current Cardiology Reports</i> , 2016, 18, 76.	2.9	10
142	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for AtrialÂFibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 170-180.	3.2	44
143	Does catheter ablation reduce mortality and stroke in patients with atrial fibrillation? Patient selection or causality?. <i>European Heart Journal</i> , 2016, 37, 2488-2489.	2.2	5
144	Venous thromboembolism in patients with implantable cardioverter-defibrillators. <i>Europace</i> , 2016, 19, euw124.	1.7	5

#	ARTICLE	IF	CITATIONS
145	To burn or to freeze: a burning question yet to be resolved. <i>European Heart Journal</i> , 2016, 37, 2866-2868.	2.2	3
146	30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. <i>International Journal of Cardiology</i> , 2016, 225, 30-36.	1.7	45
147	Left ventricular performance during triggered left ventricular pacing in patients with cardiac resynchronization therapy and left bundle branch block. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 46, 345-351.	1.3	1
148	Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2016, 375, 1221-1230.	27.0	1,350
149	Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). <i>American Heart Journal</i> , 2016, 179, 136-141.	2.7	29
150	An anterior left ventricular lead position is associated with increased mortality and non-response in cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2016, 222, 157-162.	1.7	13
151	Study Design and Cohort Description of DEFIBâ€WOMEN: A National Danish Study in Patients with an ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1261-1268.	1.2	11
152	Failure of ICD therapy in lethal arrhythmogenic right ventricular cardiomyopathy type 5 caused by the TMEM43 p.Ser358Leu mutation. <i>HeartRhythm Case Reports</i> , 2016, 2, 217-222.	0.4	2
153	Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication. <i>Drugs - Real World Outcomes</i> , 2016, 3, 279-288.	1.6	5
154	Repeated molecular genetic analysis in Brugada syndrome revealed a novel disease-associated large deletion in the SCN5A gene. <i>HeartRhythm Case Reports</i> , 2016, 2, 261-264.	0.4	2
155	Normativity under change. <i>Nursing Ethics</i> , 2016, 23, 328-338.	3.4	2
156	Retrieval of Medtronic Micra Transcatheter Pacing System after tether removal. <i>Europace</i> , 2016, 18, 1202-1202.	1.7	7
157	Longevity of implantable cardioverter-defibrillators: still a long way to go. <i>Europace</i> , 2016, 18, 1285-1286.	1.7	2
158	Single-coil and dual-coil defibrillator leads and association with clinical outcomes in a complete Danish nationwide ICD cohort. <i>Heart Rhythm</i> , 2016, 13, 706-712.	0.7	20
159	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	1.7	121
160	Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. <i>Europace</i> , 2016, 18, 413-419.	1.7	22
161	Two Cases of Ventricular Proarrhythmia from Automatic Threshold Measurement Features in a CRTD and an ICD. , 2015, 20, 604-608.		1
162	Attitudes toward Catheter Ablation for Atrial Fibrillation: A Nationwide Survey among Danish Cardiologists. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1166-1172.	1.2	0

#	ARTICLE	IF	CITATIONS
163	Refusing Implantable Cardioverter Defibrillator (ICD) Replacement in Elderly Persons-The Same as Giving Up Life: A Qualitative Study. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1275-1286.	1.2	7
164	Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment. European Heart Journal, 2015, 36, 2484-2490.	2.2	76
165	Radiofrequency ablation of accessory pathways in patients with the Wolff-Parkinson-White syndrome: the long-term mortality and risk of atrial fibrillation. Europace, 2015, 17, 117-122.	1.7	31
166	Implantable cardioverter-defibrillators and subsequent cancer risk: a nationwide population-based cohort study. Europace, 2015, 17, 902-908.	1.7	9
167	Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace, 2015, 17, 370-378.	1.7	154
168	Ankyrin-2 variants associated with idiopathic ventricular fibrillation storm in patients with intermittent early repolarization pattern. HeartRhythm Case Reports, 2015, 1, 337-341.	0.4	7
169	Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm, 2015, 12, 2368-2375.	0.7	60
170	Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 182-188.	3.0	20
171	Thirteen-year nationwide trends in use of implantable cardioverter-defibrillators and subsequent long-term survival. Heart Rhythm, 2015, 12, 2018-2027.	0.7	31
172	Association between ventricular pacing and persistent atrial fibrillation in patients indicated to elective pacemaker replacement: Results of the Prefer for Elective Replacement MVP (PreFER MVP) randomized study. Heart Rhythm, 2015, 12, 2239-2246.	0.7	26
173	The paced electrocardiogram cannot be used to identify left and right ventricular pacing sites in cardiac resynchronization therapy: validation by cardiac computed tomography. Europace, 2015, 17, 432-438.	1.7	8
174	Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial. International Journal of Cardiology, 2015, 198, 108-114.	1.7	33
175	The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace, 2015, 17, 48-55.	1.7	42
176	Left and right ventricular lead positions are imprecisely determined by fluoroscopy in cardiac resynchronization therapy: a comparison with cardiac computed tomography. Europace, 2014, 16, 1334-1341.	1.7	43
177	Need for real-world data on management of the (potentially) failing lead. Europace, 2014, 16, 1105-1106.	1.7	1
178	The patient perspective on the Riata defibrillator lead advisory: A Danish nationwide study. Heart Rhythm, 2014, 11, 2148-2155.	0.7	7
179	Prospective nationwide fluoroscopic and electrical longitudinal follow-up of recalled Riata defibrillator leads in Denmark. Heart Rhythm, 2014, 11, 2141-2147.	0.7	13
180	Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. European Heart Journal, 2014, 35, 1186-1194.	2.2	653

#	ARTICLE	IF	CITATIONS
181	Managed ventricular pacing compared with conventional dual-chamber pacing for elective replacement in chronically paced patients: Results of the Prefer for Elective Replacement Managed Ventricular Pacing randomized study. Heart Rhythm, 2014, 11, 992-1000.	0.7	36
182	His or para-His pacing preserves left ventricular function in atrioventricular block: a double-blind, randomized, crossover study. Europace, 2014, 16, 1189-1196.	1.7	144
183	Can progression to permanent atrial fibrillation be prevented by pacing?: Figure 1. European Heart Journal, 2014, 35, 2349-2351.	2.2	1
184	Health economic evaluation of single-lead atrial pacing vs. dual-chamber pacing in sick sinus syndrome. Europace, 2014, 16, 866-872.	1.7	6
185	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm, 2014, 11, 1304-1323.	0.7	1,077
186	New approach to implantable cardioverter-defibrillators in small pediatric patients: Dorsal positioning of superior vena cava shock lead in a 3-year-old. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 358-360.	0.8	0
187	Pneumothorax in cardiac pacing: a population-based cohort study of 28 860 Danish patients. Europace, 2012, 14, 1132-1138.	1.7	84
188	Atrial fibrillation in patients with sick sinus syndrome: the association with PQ-interval and percentage of ventricular pacing. Europace, 2012, 14, 682-689.	1.7	60
189	Long-term outcome of ablative therapy of post-operative atrial tachyarrhythmias in patients with tetralogy of Fallot: a European multi-centre study. Europace, 2012, 14, 522-527.	1.7	43
190	Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation. New England Journal of Medicine, 2012, 367, 1587-1595.	27.0	574
191	Pacing in sinus node disease to prevent atrial fibrillation. Expert Review of Cardiovascular Therapy, 2012, 10, 851-858.	1.5	6
192	A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. European Heart Journal, 2011, 32, 686-696.	2.2	241
193	Very long term follow-up of cardiac resynchronization therapy: Clinical outcome and predictors of mortality. European Journal of Heart Failure, 2008, 10, 796-801.	7.1	37
194	Pacing mode selection in patients with sick sinus syndrome. Danish Medical Bulletin, 2007, 54, 1-17.	0.3	7
195	A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome. Journal of the American College of Cardiology, 2003, 42, 614-623.	2.8	467
196	Regional myocardial perfusion during chronic biventricular pacing and after acute change of the pacing mode in patients with congestive heart failure and bundle branch block treated with an atrioventricular sequential biventricular pacemaker. European Journal of Heart Failure, 2003, 5, 179-186.	7.1	28
197	Atrioventricular Conduction During Long-Term Follow-Up of Patients With Sick Sinus Syndrome. Circulation, 1998, 98, 1315-1321.	1.6	112
198	Heart Failure and Echocardiographic Changes During Long-term Follow-up of Patients With Sick Sinus Syndrome Randomized to Single-Chamber Atrial or Ventricular Pacing. Circulation, 1998, 97, 987-995.	1.6	210

#	ARTICLE	IF	CITATIONS
199	Lead complications after cardiac surgery in patients with cardiac implantable electronic devices. European Journal of Cardio-thoracic Surgery, 0, , .	1.4	1